Last week, President Donald Trump announced his "Initiative to Stop Opioid Abuse" during a speech in New Hampshire, one of the states hardest hit ...
read more
Attorney General Jeff Sessions wants a wide-scale crackdown on the legal cannabis industry. However, negative reactions to his plan from a number of U.S. ...
read more
Houston and Harris County area law enforcement leaders weigh in on the need for drug policy reforms in the United States.
read more
By Jay Jenkins and Katharine Neill Harris In an op-ed for the Houston Chronicle, Jenkins and fellow Neill Harris urge Texas lawmakers to support ...
read more
Drug policy fellow Katharine A. Neill explains why establishing heroin-assisted treatment programs, which provide severely addicted individuals with controlled access to pharmaceutical-grade heroin, could ...
read more
Drug Policy Program director Bill Martin summarizes the scientific and fiscal evidence supporting the efficacy of syringe exchange programs and outlines a framework for ...
read more
Using charts, figures and graphs of this survey data originally created by former career intelligence analyst Brian C. Bennett and updated by the Drug ...
read more
April 20, 2015 Ethan Nadelmann, executive director of the Drug Policy Alliance and a leading advocate for domestic and international drug policy reform, speaking ...
Policy regarding drugs, both legal and illegal and explicitly including alcohol, poses some of the most prominent and perplexing issues facing modern societies. For nearly a century, the United States has been an active proponent of the punitive prohibition of illicit drugs. Unfortunately, the “War on Drugs” has been largely unsuccessful; prosecution of illegal drug consumption has filled our prisons without significantly reducing crime, decreasing homelessness, preventing overdose deaths.
William Martin, Ph.D., is the Harry and Hazel Chavanne Senior Fellow in Religion and Public Policy at the Baker Institute and the Chavanne Emeritus ...
Read more about this expert
Katharine Neill Harris, Ph.D., is the Alfred C. Glassell, III, Fellow in Drug Policy at the Baker Institute. Her current research focuses on state ...
Read more about this expert
